

17 August 2026

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

Sub: Appointment of Ms. Jill Mary De Simone (DIN:11483134) Director at the 28th Annual General Meeting ('AGM') of the Company

We wish to inform you that Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), shareholders at the 28th Annual General Meeting ('AGM') of the Company, held on Thursday, August 13, 2026, through video conferencing / other audiovisual means have approved the appointment of Ms. Jill Mary De Simone (DIN:11483134) as an Independent Director of the Company.

The details as required under Regulation 30 of the Listing Regulations, read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, are enclosed as **Annexure I** for your records.

The above information is being made available on the website of the Company <https://www.indegene.com/>

Kindly take the above-said information on record.

For Indegene Limited

Srishti Ramesh Kaushik
Company Secretary and Compliance Officer
Encl: A/a



Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-
560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
compliance.officer@indegene.com
www.indegene.com

CIN: L73100KA1998PLC102040

Annexure – I

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025–CFD–POD2/1/3762/2026 dated January 30, 2026.

Sl. No	Particulars	Details
1.	Name of the Director	Ms. Jill Mary De Simone (DIN:11483134)
2.	Reason for change	The Members of the Company have approved the appointment at the 28 th Annual General Meeting
3.	Date of Appointment & term of appointment	January 22, 2026 Term: For a term of 3 years with effect from January 22, 2026 to January 21, 2029 (both days inclusive).
4.	Brief Profile	Ms. Jill Mary De Simone is an accomplished biopharmaceutical executive and board director with extensive experience in driving growth, innovation, and governance across global healthcare organizations. A former President of U.S. Oncology at Merck, her career spans leadership roles at Merck, Teva, and Bristol Myers Squibb, where she managed full P&L responsibilities and launched transformative therapies in oncology, HIV, women's health, and general medicine. Currently, she advises preclinical and early-stage companies on commercialization and leadership transitions, serves on boards of public and private life sciences companies, and chairs advisory boards focused on AI in healthcare. Renowned for her strategic acumen, authentic leadership, and commitment to purpose-driven cultures, she brings deep industry expertise and a passion for mentoring leaders and shaping governance.
5.	Disclosure of relationships between Directors	Not related to any Director of the Company
6.	Information as required pursuant to BSE Circular with ref. no. LIST/ COMP/ 14/ 2018– 19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/24, dated June 20, 2018.	Ms. Jill Mary De Simone is not debarred from holding the office of Director by virtue of order of SEBI or any other authority.